RETRONEXT
LIVE

Serial Number

79376165

Owner

BioDesign Lab Co., Ltd.

Attorney

Jong Park

Filing Date

Jun 22, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RETRONEXT Trademark

Serial Number: 79376165 • Registration: 7510376

RETRONEXT is a trademark filed by BioDesign Lab Co., Ltd. on June 22, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BioDesign Lab Co., Ltd.

#C5-613, 80, Jigok-ro,

Entity Type: 03

Trademark Details

Filing Date

June 22, 2023

Registration Date

September 24, 2024

Published for Opposition

July 9, 2024

Goods & Services

Gene transfer agents for preventing and treating human vector-borne diseases; biological preparations, namely, biological vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations, namely, biological recombinant vectors for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); biological preparations for gene recombination for medical, medicinal or veterinary purposes for the treatment and prevention of cancer and rare genetic disorders, namely, hemophilia, thalassemia, sickle cell disease (SCD), severe combined immunodeficiency (SCID), and Leber hereditary optic neuropathy (LHON); nucleic acids for medical, medicinal or veterinary purposes; biopharmaceuticals for the treatment of auto-immune diseases; biopharmaceuticals for the treatment of cancer; diagnostic biomarker reagents for medical purposes; reagents for use in medical genetic testing; pharmaceutical preparations for gene therapy and diagnosis of auto-immune diseases and cancer; pharmaceutical preparations for the diagnosis and the treatment of auto-immune diseases; anti-cancer preparations; antibiotics; anti-viral agents; anti-infectives; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer cells; cells for medical purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 22, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 2, 2025 FICS
FINAL DISPOSITION PROCESSED
Mar 2, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 25, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 8, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 8, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 24, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 24, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 24, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 9, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 19, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 30, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
May 30, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 30, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
May 30, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 30, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 23, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 3, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 3, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 16, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 15, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 11, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 15, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 11, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 10, 2023 REPR